Viracta Therapeutics KOL Webinar on Nana-val for the Treatment of Epstein-Barr Virus-Positive (EBV+) Solid Tumors
About The Event
The webinar will feature a presentation from Key Opinion Leader (KOL) Ezra Cohen, MD, FRCPSC, FASCO (Chief of Hematology/Oncology, Department of Medicine and Co-director of the Gleiberman Head and Neck Cancer Center, University of California, San Diego), who will discuss the current treatment landscape in nasopharyngeal carcinoma (NPC) and the potential of Viracta’s all-oral combination product Nana-val (nanatinostat and valganciclovir) to address the unmet needs of NPC patients with EBV+ disease.
Additionally, members of Viracta’s management team will provide an overview of the ongoing Phase 1b/2 clinical trial evaluating Nana-val in patients with recurrent or metastatic NPC and other advanced EBV+ solid tumors. Preclinical data supporting Nana-val’s use in solid tumors and the program’s future outlook will also be discussed.
A live question and answer session will follow the formal presentation.